Abstract
Objective: Therapeutic drug monitoring (TDM) of tacrolimus in whole blood is essential to optimize clinical outcomes and reduce toxicity. However, the relationship between blood concentrations and therapeutic efficacy is unclear, probably because it does not reflect tacrolimus concentration at the active site. In this preliminary study, our aims were to validate a new method for tacrolimus quantification into the target cells (peripheral blood mononuclear cells, PBMCs), in a cohort of 24 pediatric liver recipients after a median follow-up of 5.23 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
